| June 2006 |
Phase II study of BufferGel®-Duet™ for therapy of bacterial vaginosis therapy agreed to, anticipated initiation in Q2, 2007 |
| October 2005 |
Duet Phase I safety and acceptability study completed: BufferGel with Duet safe, acceptable, and fit 97% of trial participants
|
| July 2005 |
BufferGel Phase III contraceptive trials completed: Demonstrated contraceptive efficacy and safety of BufferGel plus diaphragm |
| June 2005 |
Received NIH funding for further development of Duet device design and manufacturing |
| Feb 2005 |
Phase II/IIB HIV prevention trial of BufferGel and PRO 2000 begins |
| May 2004 |
With Starphama Holdings Ltd, received NIH funding for creation of a second generation microbicide based on BufferGel combined with Starpharma’s “dendrimer” technology. |
